![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Once-daily NS5A Inhibitor (BMS-790052) Plus Peginterferon-alpha-2a And Ribavirin Produces High Rates Of Extended Rapid Virologic Response In Treatment-naïve HCV-genotype 1 Subjects: Phase 2a Trial - Bristol-Myers Squibb Study AI444014
|
|
|
Reported by Jules Levin
EASL, The International Liver Congress, Vienna, Austria, 2010 Apr 17,
Late-breaker Presentation
S. Pol, G. Everson, R. Ghalib, V. Rustgi, C. Martorell, H. Tatum, J. Lim, C. Hezode,
U. Diva, P.D. Yin, and R. Hindes
![](../images/041910/041910-12/image002.gif)
![](../images/041910/041910-12/image004.gif)
![](../images/041910/041910-12/image006.gif)
![](../images/041910/041910-12/image008.gif)
![](../images/041910/041910-12/image010.gif)
![](../images/041910/041910-12/image012.gif)
![](../images/041910/041910-12/image014.gif)
![](../images/041910/041910-12/image016.gif)
![](../images/041910/041910-12/image018.gif)
![](../images/041910/041910-12/image020.gif)
* Related to study regimen
![](../images/041910/041910-12/key-1.gif)
![](../images/041910/041910-12/image024.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|